Lymphoma & CLL Trials

FDA accepts new drug application for parsaclisib for R/R FL, MZL, and MCL

Non-Hodgkin lymphomas (NHLs) are a varied group of lymphatic cancers that may be indolent or aggressive, and while some...

Novel targeted therapies for R/R marginal zone lymphoma

It has been challenging to define an optimal therapeutic approach for relapsed patients with marginal zone lymphoma (MZL) due to disease...

FDA grants priority review to tisagenlecleucel for relapsed/refractory follicular lymphoma

On October 27, 2021, Novartis announced that the U.S. Food and Drug Administration (FDA) had accepted a...

Updated results from the ELARA trial of tisa-cel in R/R follicular lymphoma

The Lymphoma Hub has previously reported on the interim analysis of the ELARA trial (NCT03568461) for adult patients with...

Phase II MAGNOLIA trial: Efficacy and safety of zanubrutinib in marginal zone lymphoma

Bruton’s tyrosine kinase (BTK) inhibitors provide a highly selective mechanism of action in marginal zone...

Zanubrutinib granted accelerated approval by the FDA for the treatment of patients with R/R MZL

On September 15, 2021, the U.S. Food and Drug Administration (FDA) granted accelerated approval to...

Humoral and cellular responses to tisagenlecleucel

Chimeric antigen receptor (CAR) T-cell therapy has elicited high-response rates in patients with relapsed or refractory (R/R) B-cell malignancies...

SOHO 2019 | The future of cellular therapy in hematological malignancies

A series of talks were made at SOHO 2019 on current and future advances and potential of cellular therapies in hematological...